Enterprise Value

-29.22M

Cash

113M

Avg Qtr Burn

N/A

Short % of Float

0.38%

Insider Ownership

32.69%

Institutional Own.

10.61%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
ABI-4334 Details
Liver disease, Liver infection, Hepatitis B

Phase 1b

Data readout

ABI-5366 Details
Genital herpes (HSV)

Phase 1a

Data readout

Vebicorvir (VBR, ABI-H0731) Details
Liver infection, Chronic liver disease, Hepatitis B

Failed

Discontinued

ABI-H2158 Details
Liver infection, Liver disease, Hepatitis B

Failed

Discontinued

ABI-H3733 Details
Liver disease, Hepatitis B, Liver infection

Failed

Discontinued